Pfizer Inc. (NYSE:PFE) Shares Acquired by Schrum Private Wealth Management LLC

Schrum Private Wealth Management LLC boosted its holdings in Pfizer Inc. (NYSE:PFE) by 51.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 31,302 shares of the biopharmaceutical company’s stock after acquiring an additional 10,658 shares during the period. Schrum Private Wealth Management LLC’s holdings in Pfizer were worth $906,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. acquired a new position in shares of Pfizer during the 1st quarter worth approximately $315,000. GSA Capital Partners LLP acquired a new position in shares of Pfizer in the first quarter worth $439,000. Koshinski Asset Management Inc. lifted its position in shares of Pfizer by 20.5% in the first quarter. Koshinski Asset Management Inc. now owns 24,265 shares of the biopharmaceutical company’s stock valued at $673,000 after acquiring an additional 4,130 shares in the last quarter. Dearborn Partners LLC boosted its stake in shares of Pfizer by 18.4% during the first quarter. Dearborn Partners LLC now owns 32,683 shares of the biopharmaceutical company’s stock valued at $907,000 after acquiring an additional 5,077 shares during the last quarter. Finally, Private Management Group Inc. increased its position in Pfizer by 270.7% during the 1st quarter. Private Management Group Inc. now owns 26,579 shares of the biopharmaceutical company’s stock worth $738,000 after purchasing an additional 19,409 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. The trade was a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.06% of the company’s stock.

Pfizer Trading Up 0.3 %

PFE traded up $0.08 on Wednesday, reaching $26.27. 8,806,469 shares of the company’s stock were exchanged, compared to its average volume of 37,594,039. The company has a market cap of $148.87 billion, a price-to-earnings ratio of 35.39, a PEG ratio of 0.83 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $31.54. The company’s 50 day moving average is $28.80 and its 200-day moving average is $28.68.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.17) EPS. Equities analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.40%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s payout ratio is 227.03%.

Wall Street Analyst Weigh In

PFE has been the topic of several analyst reports. Barclays raised their price target on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Sanford C. Bernstein assumed coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Finally, Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Eight analysts have rated the stock with a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $33.58.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.